Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)
The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR)....
Saved in:
Published in | JACC. Cardiovascular interventions Vol. 8; no. 1 Pt A; p. 92 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.01.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 1876-7605 1876-7605 |
DOI | 10.1016/j.jcin.2014.09.009 |
Cover
Abstract | The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).
Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.
The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure.
Study enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74).
The EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628). |
---|---|
AbstractList | The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).
Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.
The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure.
Study enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74).
The EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628). The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).OBJECTIVESThe purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.BACKGROUNDFemoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure.METHODSThe multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with Rutherford Class 1 to 4 and lesions of target lesion length ≥4 cm, vessel diameter 5 to 7 mm were enrolled and randomly divided into ELA + PTA and PTA groups by a 2:1 ratio. The primary efficacy endpoint was target lesion revascularization (TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days post-procedure.Study enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74).RESULTSStudy enrollment was stopped at 250 patients due to early efficacy demonstrated at a prospectively-specified interim analysis. A total of 169 ELA + PTA subjects (62.7% male; mean age 68.5 ± 9.8 years) and 81 PTA patients (61.7% male; mean age 67.8 ± 10.3 years) were enrolled. Mean lesion length was 19.6 ± 12.0 cm versus 19.3 ± 11.9 cm, and 30.5% versus 36.8% of patients exhibited total occlusion. ELA + PTA subjects demonstrated superior procedural success (93.5% vs. 82.7%; p = 0.01) with significantly fewer procedural complications. ELA + PTA and PTA subject 6-month freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (p < 0.001), respectively. ELA + PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% confidence interval: 0.31 to 0.74).The EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628).CONCLUSIONSThe EXCITE ISR trial is the first large, prospective, randomized study to demonstrate superiority of ELA + PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628). |
Author | Colon-Hernandez, Pedro J Stark, Matthew A Patlola, Raghotham Beasley, Robert Dippel, Eric J Makam, Prakash George, Jon C Soukas, Peter Kovach, Richard Metzger, D Christopher Mena-Hurtado, Carlos Walker, Craig |
Author_xml | – sequence: 1 givenname: Eric J surname: Dippel fullname: Dippel, Eric J email: dippel@cvmedpc.com organization: Genesis Medical Center, Davenport, Iowa. Electronic address: dippel@cvmedpc.com – sequence: 2 givenname: Prakash surname: Makam fullname: Makam, Prakash organization: Cardiology Associates of Northwest Indiana, Munster, Indiana – sequence: 3 givenname: Richard surname: Kovach fullname: Kovach, Richard organization: Deborah Heart and Lung Center, Browns Mills, New Jersey – sequence: 4 givenname: Jon C surname: George fullname: George, Jon C organization: Deborah Heart and Lung Center, Browns Mills, New Jersey – sequence: 5 givenname: Raghotham surname: Patlola fullname: Patlola, Raghotham organization: Cardiovascular Clinic of Hattiesburg, Hattiesburg, Mississippi – sequence: 6 givenname: D Christopher surname: Metzger fullname: Metzger, D Christopher organization: Wellmont Holston Valley, Kingsport, Tennessee – sequence: 7 givenname: Carlos surname: Mena-Hurtado fullname: Mena-Hurtado, Carlos organization: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut – sequence: 8 givenname: Robert surname: Beasley fullname: Beasley, Robert organization: Division of Radiology, Mount Sinai Heart Institute, Miami Beach, Florida – sequence: 9 givenname: Peter surname: Soukas fullname: Soukas, Peter organization: The Miriam Hospital, Providence, Rhode Island – sequence: 10 givenname: Pedro J surname: Colon-Hernandez fullname: Colon-Hernandez, Pedro J organization: Centro Cardiovascular de Puerto Rico y el Caribe, San Juan, Puerto Rico – sequence: 11 givenname: Matthew A surname: Stark fullname: Stark, Matthew A organization: The Spectranetics Corporation, Colorado Springs, Colorado – sequence: 12 givenname: Craig surname: Walker fullname: Walker, Craig organization: Cardiovascular Institute of the South, Houma, Louisiana |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25499305$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkUtr4zAUhcXQYfr8A7MoWrYLeyTZkqvuSkjbQKCQeDG7oFoyo6CHK8kwmX_eXeVMH9noXu49nPNxdQqOnHcKgJ8YlRhh9mtbbjvtSoJwXSJeIsS_gRN807CiYYgeHfTH4DTGLUIM8Yb8AMeE1pxXiJ6A15Vw0lv9T0nYeZeCNya3MY1yB30P1d9OWxWgETG_Iv1RQXXJ2x3sfYApKJGscmmS9sr64Ac_GJ2UMFC7IqZpF9RUfdTxNg910nmZZ6NJEfbBW5hd4fz3bNHO4WK9yq6T4mqaTNHLffQB5-yLc73nnFDaQ5T7L5R2nr0WrljvUVafKNfn4HsvTFQX7_UMtPfzdvZYLJ8eFrO7ZTGQuk4F41Rg3kuKJeurppGoYw0XdY1qnLtGVl0jGeckq58pQ30-MiUCK3SDpKTVGbj6bzsE_zLm-I3VsVPGCKf8GDeYUVJXlCCSpZfv0vHZKrkZgrYi7DYfv1W9AbZ8n2s |
ContentType | Journal Article |
Contributor | Lee, Arthur Raja, M Laiq Luft, Ulrich Lowry, Richard Harrison, Lonnie Venkatesan, Jayaraman Salvaggio, Louis Gallino, Robert Karenko, Barbara Van Roy, Daniel Vouyouka, Ageliki Ingraldi, Agostino Shimshak, Thomas Goldstein, Jeffrey Wilkins, Robert Chamberlin, Jack Colleran, John Sakhuja, Rahul Mustapha, Jihad Zughaib, Marcel Nelson, Brian Eaves, William Ramaiah, Venkatesh Uceda, Pablo Bose, Rahul Yoho, Jason Laird, John Weatherford, David Foster, Robert Mego, David Mishkel, Gregory Shammas, Nicolas Veerina, Kalyan Stewart, Jeffrey Mangalmurti, Sarang O'Meara, James Asfour, Wail Panneton, Jean Wheatley, Grayson Lookstein, Robert Jacobs, Donald Trimm, James Falcone, Wayne Bernardo, Nelson Kollmeyer, Kenneth Babaev, Anvar Carr, Jeff Robken, Jon Janzer, Sean Rossbach, Mario Pratsos, Antonis Marrero, Edwin Pérez Bunch, Frank Gupta, Anjan Pastor-Cervantes, Juan Menuet, Robert Cawich, Ian Das, Tony Rodriguez, Julio Deshmukh, Deepak |
Contributor_xml | – sequence: 1 givenname: Jon surname: Robken fullname: Robken, Jon – sequence: 2 givenname: Nicolas surname: Shammas fullname: Shammas, Nicolas – sequence: 3 givenname: Ulrich surname: Luft fullname: Luft, Ulrich – sequence: 4 givenname: Jeffrey surname: Goldstein fullname: Goldstein, Jeffrey – sequence: 5 givenname: Gregory surname: Mishkel fullname: Mishkel, Gregory – sequence: 6 givenname: Jeffrey surname: Stewart fullname: Stewart, Jeffrey – sequence: 7 givenname: David surname: Mego fullname: Mego, David – sequence: 8 givenname: Ian surname: Cawich fullname: Cawich, Ian – sequence: 9 givenname: Lonnie surname: Harrison fullname: Harrison, Lonnie – sequence: 10 givenname: Wail surname: Asfour fullname: Asfour, Wail – sequence: 11 givenname: Agostino surname: Ingraldi fullname: Ingraldi, Agostino – sequence: 12 givenname: Louis surname: Salvaggio fullname: Salvaggio, Louis – sequence: 13 givenname: Brian surname: Nelson fullname: Nelson, Brian – sequence: 14 givenname: Thomas surname: Shimshak fullname: Shimshak, Thomas – sequence: 15 givenname: Rahul surname: Sakhuja fullname: Sakhuja, Rahul – sequence: 16 givenname: Grayson surname: Wheatley fullname: Wheatley, Grayson – sequence: 17 givenname: Julio surname: Rodriguez fullname: Rodriguez, Julio – sequence: 18 givenname: Venkatesh surname: Ramaiah fullname: Ramaiah, Venkatesh – sequence: 19 givenname: Nelson surname: Bernardo fullname: Bernardo, Nelson – sequence: 20 givenname: Kenneth surname: Kollmeyer fullname: Kollmeyer, Kenneth – sequence: 21 givenname: Pablo surname: Uceda fullname: Uceda, Pablo – sequence: 22 givenname: Jack surname: Chamberlin fullname: Chamberlin, Jack – sequence: 23 givenname: Tony surname: Das fullname: Das, Tony – sequence: 24 givenname: Robert surname: Foster fullname: Foster, Robert – sequence: 25 givenname: James surname: Trimm fullname: Trimm, James – sequence: 26 givenname: Robert surname: Gallino fullname: Gallino, Robert – sequence: 27 givenname: John surname: Laird fullname: Laird, John – sequence: 28 givenname: Frank surname: Bunch fullname: Bunch, Frank – sequence: 29 givenname: Anjan surname: Gupta fullname: Gupta, Anjan – sequence: 30 givenname: Jean surname: Panneton fullname: Panneton, Jean – sequence: 31 givenname: Deepak surname: Deshmukh fullname: Deshmukh, Deepak – sequence: 32 givenname: Donald surname: Jacobs fullname: Jacobs, Donald – sequence: 33 givenname: Antonis surname: Pratsos fullname: Pratsos, Antonis – sequence: 34 givenname: Sean surname: Janzer fullname: Janzer, Sean – sequence: 35 givenname: Sarang surname: Mangalmurti fullname: Mangalmurti, Sarang – sequence: 36 givenname: Anvar surname: Babaev fullname: Babaev, Anvar – sequence: 37 givenname: William surname: Eaves fullname: Eaves, William – sequence: 38 givenname: Robert surname: Wilkins fullname: Wilkins, Robert – sequence: 39 givenname: Wayne surname: Falcone fullname: Falcone, Wayne – sequence: 40 givenname: David surname: Weatherford fullname: Weatherford, David – sequence: 41 givenname: Jihad surname: Mustapha fullname: Mustapha, Jihad – sequence: 42 givenname: Barbara surname: Karenko fullname: Karenko, Barbara – sequence: 43 givenname: John surname: Colleran fullname: Colleran, John – sequence: 44 givenname: Edwin Pérez surname: Marrero fullname: Marrero, Edwin Pérez – sequence: 45 givenname: Juan surname: Pastor-Cervantes fullname: Pastor-Cervantes, Juan – sequence: 46 givenname: M Laiq surname: Raja fullname: Raja, M Laiq – sequence: 47 givenname: Marcel surname: Zughaib fullname: Zughaib, Marcel – sequence: 48 givenname: Kalyan surname: Veerina fullname: Veerina, Kalyan – sequence: 49 givenname: Robert surname: Menuet fullname: Menuet, Robert – sequence: 50 givenname: Jayaraman surname: Venkatesan fullname: Venkatesan, Jayaraman – sequence: 51 givenname: Robert surname: Lookstein fullname: Lookstein, Robert – sequence: 52 givenname: Ageliki surname: Vouyouka fullname: Vouyouka, Ageliki – sequence: 53 givenname: Mario surname: Rossbach fullname: Rossbach, Mario – sequence: 54 givenname: Jason surname: Yoho fullname: Yoho, Jason – sequence: 55 givenname: Rahul surname: Bose fullname: Bose, Rahul – sequence: 56 givenname: Jeff surname: Carr fullname: Carr, Jeff – sequence: 57 givenname: Richard surname: Lowry fullname: Lowry, Richard – sequence: 58 givenname: Arthur surname: Lee fullname: Lee, Arthur – sequence: 59 givenname: James surname: O'Meara fullname: O'Meara, James – sequence: 60 givenname: Daniel surname: Van Roy fullname: Van Roy, Daniel |
Copyright | Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
CorporateAuthor | EXCITE ISR Investigators |
CorporateAuthor_xml | – name: EXCITE ISR Investigators |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.jcin.2014.09.009 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1876-7605 |
ExternalDocumentID | 25499305 |
Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 4.4 457 4G. 53G 5GY 5VS 7-5 8P~ AACTN AAEDT AAEDW AAIKJ AALRI AAOAW AAQFI AAXUO ABBQC ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACGFO ACGFS ACRPL ADBBV ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AEVXI AEXQZ AFCTW AFETI AFJKZ AFRHN AFTJW AGHFR AGYEJ AITUG AJRQY ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P FDB FEDTE FNPLU GBLVA H13 HVGLF HZ~ IXB J1W M41 MO0 N9A NPM O-L O9- OAUVE OA~ OK1 OL0 P-8 P-9 P2P PC. Q38 RIG ROL SDF SEL SES SSZ W8F Z5R 7X8 AAYWO EFKBS EFLBG ~HD |
ID | FETCH-LOGICAL-p244t-695a19fd51d6f377d0c679a44041c677d3c7d6992244b560f06052a1e080dd53 |
ISSN | 1876-7605 |
IngestDate | Sun Sep 28 14:01:52 EDT 2025 Thu Apr 03 07:01:33 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 Pt A |
Keywords | percutaneous transluminal angioplasty excimer laser atherectomy peripheral artery disease femoropopliteal artery in-stent restenosis randomized controlled trial |
Language | English |
License | Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p244t-695a19fd51d6f377d0c679a44041c677d3c7d6992244b560f06052a1e080dd53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 25499305 |
PQID | 1652435202 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_1652435202 pubmed_primary_25499305 |
PublicationCentury | 2000 |
PublicationDate | 2015-01-01 |
PublicationDateYYYYMMDD | 2015-01-01 |
PublicationDate_xml | – month: 01 year: 2015 text: 2015-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | JACC. Cardiovascular interventions |
PublicationTitleAlternate | JACC Cardiovasc Interv |
PublicationYear | 2015 |
References | 25560374 - Nat Rev Cardiol. 2015 Feb;12(2):63 |
References_xml | – reference: 25560374 - Nat Rev Cardiol. 2015 Feb;12(2):63 |
SSID | ssj0060972 |
Score | 2.532264 |
Snippet | The purpose of this study was to evaluate the safety and efficacy of excimer laser atherectomy (ELA) with adjunctive percutaneous transluminal angioplasty... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 92 |
SubjectTerms | Aged Alloys Amputation Angioplasty, Balloon - adverse effects Angioplasty, Balloon - instrumentation Angioplasty, Balloon - mortality Atherectomy - adverse effects Atherectomy - instrumentation Atherectomy - methods Atherectomy - mortality Chronic Disease Combined Modality Therapy Constriction, Pathologic Female Femoral Artery - physiopathology Femoral Artery - surgery Humans Laser Therapy - adverse effects Laser Therapy - instrumentation Laser Therapy - methods Laser Therapy - mortality Lasers, Excimer - adverse effects Lasers, Excimer - therapeutic use Limb Salvage Male Middle Aged Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - mortality Peripheral Arterial Disease - surgery Peripheral Arterial Disease - therapy Popliteal Artery - physiopathology Popliteal Artery - surgery Prospective Studies Prosthesis Design Recurrence Stents Time Factors Treatment Outcome United States Vascular Patency |
Title | Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/25499305 https://www.proquest.com/docview/1652435202 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1876-7605 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0060972 issn: 1876-7605 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier Free Content customDbUrl: eissn: 1876-7605 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0060972 issn: 1876-7605 databaseCode: IXB dateStart: 20080201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1876-7605 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0060972 issn: 1876-7605 databaseCode: .~1 dateStart: 20080201 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1876-7605 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0060972 issn: 1876-7605 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6SFEovpe-mL6ZQSotRsN52b6lrk7R2GmwFfBOSVgKlsaRGMpT88946s7vyqm4KaS9iWcvSwHzaeey3M4y9iThVEHFTw7cH3EB7bRsRLYZW6sfDJHMcLrZiZife0Znzeekud3ahw1paN_FBcnXtuZL_0SrOoV7plOw_aHbzUJzAMeoXr6hhvN5Ix_Oo4OUqv0p5Szm_wGHd1olOfyT5KqWcJErTE64e5ehXkqOpKeZ4a0aE27IqKzqSLOpwGKh-_E207ijKOhfUuZyoRqIVQL2-aGp9OGW8HOEa2DtezHuyDwg6rjRHr5-K13dkHWlZF0JWEifoijPR4gRjUQ3EWAhx5loclcJoHevD0eiA6Cu_sWs7hM5N7PAprypJTSAboLfFZtE3-XGcXuKo3qTJv-DzZL-sThECQVkS2wlqC0Jlm1X-xHQ7-RO55KM9MHyvL_fW02vmlJ0YdD-H3mmjks1y4ZcN_f6wRzI1cn5wnuRUbNeURXX7Q219W8bByddwcjadhsF4GbytvhvUF434A6pJzC67ZfmeRz06jpcfW1_Do-JLlFJo5VXHwiSDcfulfw-ihDMV3GN3VRQEhxLS99lOWjxgt2eK5_GQ_dRoAY1sEMiGMgOFbBDIhg6yAaEEG2TTrVvIhhbZoJH9ARSuQeEaCNeATwWJa0Bcg8A1vFOoBoFq6MipUQ0C1UKUoCvKFqqhRTVoVL9_xILJOBgdGapJiVGhZ9wY3tCNzGHGXZN7me37vJ94_jCispsmjnxuJz73qPqz48QYXmSoNNeKzBRDNc5d-zHbK8oifcogiWKrP_DQgU5iJ47dOIsSDE9w0bQjnvFsn71u1ReiDaCNvahIy3Udmp5rYdhj9a199kTqNaxksZpQJIDQqD-7wb-fszv6C3nB9prLdfoSfe4mfiVg9wu6IeXL |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+controlled+study+of+excimer+laser+atherectomy+for+treatment+of+femoropopliteal+in-stent+restenosis%3A+initial+results+from+the+EXCITE+ISR+trial+%28EXCImer+Laser+Randomized+Controlled+Study+for+Treatment+of+FemoropopliTEal+In-Stent+Restenosis%29&rft.jtitle=JACC.+Cardiovascular+interventions&rft.au=Dippel%2C+Eric+J&rft.au=Makam%2C+Prakash&rft.au=Kovach%2C+Richard&rft.au=George%2C+Jon+C&rft.date=2015-01-01&rft.issn=1876-7605&rft.eissn=1876-7605&rft.volume=8&rft.issue=1+Pt+A&rft.spage=92&rft_id=info:doi/10.1016%2Fj.jcin.2014.09.009&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1876-7605&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1876-7605&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1876-7605&client=summon |